Strand Therapeutics Names Dr. Jason J. Luke as Chief Medical Officer

New Appointment: Strand Therapeutics has appointed Dr. Jason J. Luke as Chief Medical Officer, bringing extensive experience in cancer immunotherapy and clinical research to the company.

Dr. Luke's Background: Previously an Associate Professor at the University of Pittsburgh, Dr. Luke has led over 100 clinical studies and is recognized for his work in immuno-oncology, including significant contributions to checkpoint inhibitors and cancer vaccines.

Focus on mRNA Therapy: As CMO, Dr. Luke will oversee the clinical development strategy and focus on the ongoing first-in-human trial of STX-001, Strand's lead programmable mRNA therapy.

Strand Therapeutics Overview: The company aims to revolutionize medicine with its programmable mRNA platform, which allows for precise gene regulation and delivery, targeting various diseases, particularly in cancer treatment.